News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oraya Therapeutics's Successful INTREPID Study Outcomes Presented at EURETINA 2012 Congress


9/21/2012 9:40:33 AM

NEWARK, Calif.--(BUSINESS WIRE)--Oraya Therapeutics, Inc. today announced that the results of the INTREPID trial of radiation therapy for wet AMD were first presented during the 12th EURETINA Congress in Milan, Italy. The INTREPID study is the first sham-controlled double-masked trial to evaluate the effectiveness and safety of a one-time radiation therapy in conjunction with as-needed anti-VEGF injections for the treatment of wet AMD. A total of 21 sites in five European countries participated in the trial with a total enrollment of 230 subjects.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES